Comparison of clarithromycin triple therapy and levofloxacin triple therapy in H. pylori eradication.

Authors

  • Saif Othman Tishreen University
  • Ismael Hammad Tishreen University
  • Rana Issa Tishreen University

Abstract

Background: Helicobacter pylori is one of the bacteria widely spread around the world, and it plays an important role in several pathological conditions such as peptic ulcer disease, dyspepsia and neoplastic metaplasia in the stomach.Different treatment regimens are used to eradicate H. pylori all over the world, and the first line of treatment varies according to the region and the country due to the difference in the availability of medicines and the resistance of H. pylori to antibiotics.The most common treatment regimens used in Syria are the standard triple therapy with clarithromycin and the triple therapy based on levofloxacin

The Goal Of The Study: Comparison of the effectiveness of standard triple therapy with clarithromycin and levofloxacin based triple therapy in eradication of H. pylori

Methods: The study included 117 patients from the Digestive Diseases Division at Tishreen University Hospital for the year 2020 who were given an upper gastrointestinal endoscopy with biopsies taken to investigate Helicobacter pylori infection

The sample of H. pylori positive patients was divided into two groups: Group A was put on the standard triple therapy of clarithromycin (Cla500mg *2, Amo 1000mg *2and esostome40 mg *1) for 14 days, and group B was put on the triple therapy based on levofloxacin (Levo500mg *1, Amo1000mg *2 and esostome 40mg *1) for 14 days.

All patients had upper GI endoscopy repeated 4-6 weeks after the end of treatment, with 5 tissue biopsies taken to investigate Helicobacter pylori

Results and discussion: The study included 117 patients who fulfilled the inclusion criteria. Among these patients, H. pylori infection was positive in 86 patients, with a percentage of 73.5%.

Pylori-negative patients were excluded, and the sample of H. pylori-positive patients was divided into two groups: Group A was placed on the standard triple therapy with clarithromycin for 14 days, and group B was placed on the triple therapy based on levofloxacin for 14 days.

17 patients out of 46 patients from group A were cured, with an eradication rate of H. pylori that reached 37%, and 18 patients out of 40 patients in group B were cured with an eradication rate of H. pylori that reached 45%.

The study did not show statistically significant differences between the incidence of recovery and sex (P = 0,7), as well as between the incidence of recovery and age (P = 0,1)

Conclusion:The triple therapy based on levofloxacin showed superiority to the standard triple therapy with clarithromycin in eradicating H. pylori (45% versus 37% eradication rate, respectively).

Downloads

Published

2022-07-31

How to Cite

1.
عثمان س, حماد ا, عيسى ر. Comparison of clarithromycin triple therapy and levofloxacin triple therapy in H. pylori eradication. Tuj-hlth [Internet]. 2022Jul.31 [cited 2024Apr.28];44(3):391-403. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/12359

Issue

Vol. 44 No. 3 (2022): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Master student researches

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Most read articles by the same author(s)